{
  "abstract": "The NexAb multiplex protein microarray platform, comprising a 7,015-spot tissue lysate array and antigen-oriented protein arrays, was developed for preclinical tissue-binding and cross-reactivity assessment of therapeutic antibodies. Four anti-HER2 antibodies, trastuzumab, pertuzumab, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd), were profiled with integrated ERBB2 mRNA data. On antigen-oriented arrays, cell-synthesized HER2 bound trastuzumab and pertuzumab strongly and epitope-dependently, whereas wheat-germ HER2 showed no binding. On the tissue lysate array, trastuzumab and T-DM1 bound HER2-positive cancer cell lines and tumor tissues with nearly identical profiles (correlation coefficient r = 0.991), and T-DXd bound ERBB2-low cancer spots and 38.8% of normal human tissue spots, a profile not conserved in cynomolgus monkeys. Trastuzumab, T-DM1, and pertuzumab showed no cross-reactivity with cynomolgus monkey tissues, whereas T-DXd bound 3.1% of monkey tissue spots. NexAb enables quantitative cross-reactivity profiling relevant to preclinical safety evaluation.",
  "abstract_shown": true,
  "affiliations": [
    "JeiserBio inc."
  ],
  "article_type": "New results",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "name": "S. Matsukura"
    },
    {
      "name": "N. Sawada"
    },
    {
      "name": "M. Watanabe"
    },
    {
      "name": "I. Yabuta"
    },
    {
      "name": "G. Morisawa"
    },
    {
      "name": "Y. Kawamura"
    },
    {
      "name": "H. Nanamiya"
    },
    {
      "name": "J.-i. Imai"
    },
    {
      "affs": [
        0
      ],
      "name": "M. Takagi"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/79z6ymh7zskph.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.10.11.757820",
  "fulltext_url": "https://www.biorxiv.org/content/10.64898/2026.10.11.757820v1.full",
  "id": "79z6ymh7zskph",
  "issns": [],
  "landing_url": "https://www.biorxiv.org/content/10.64898/2026.10.11.757820v1",
  "language": null,
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "biorxiv",
      "pharmacology and toxicology"
    ],
    [
      "openalex",
      "1312|Advanced Biosensing Techniques and Applications"
    ]
  ],
  "openalex": "W7222890117",
  "pdf_url": "https://www.biorxiv.org/content/10.64898/2026.10.11.757820v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-11",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/79z6ymh7zskph.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:28:21Z",
      "native_id": "10.64898/2026.10.11.757820",
      "source": "biorxiv",
      "url": "https://www.biorxiv.org/content/10.64898/2026.10.11.757820v2"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "biorxiv:pharmacology and toxicology",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "A Multiplex Protein Microarray Platform for Preclinical Tissue Binding and Cross-Reactivity of Therapeutic Antibodies",
  "title_text": "A Multiplex Protein Microarray Platform for Preclinical Tissue Binding and Cross-Reactivity of Therapeutic Antibodies",
  "type": "preprint",
  "updated_at": "2026-10-30T12:28:27Z",
  "url": "https://research.draconitic.com/paper/79z6ymh7zskph",
  "venue": "bioRxiv",
  "versions": []
}